Fasenra approved in the US for eosinophilic granulomatosis with ...
WEB3 days ago · AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal. 2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the ...
FDA Approves Fasenra for Eosinophilic Granulomatosis With …
WEB1 day ago · September 19, 2024. During weeks 48 through 52, a 100% reduction in the OCS dose was observed in 41% of benralizumab-treated patients vs 26% of mepolizumab-treated patients. The Food and Drug Administration (FDA) has approved Fasenra ® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
FDA Approves Benralizumab for Eosinophilic Granulomatosis …
WEB2 days ago · The adjusted percentage of patients with remission at weeks 36 and 48 was 59% in the benralizumab group and 56% in the mepolizumab group (difference, 3 percentage points; 95% CI, –13 to 18; P ...
FDA Approves Benralizumab for Eosinophilic Granulomatosis with …
WEB3 days ago · The trial, which compared benralizumab to the only FDA-approved therapy for EGPA at the time, mepolizumab (Nucala), was billed by AstraZeneca as the first head-to-head non-inferiority trial of biologics in patients with EGPA. 1,2 “This approval is great news for patients with EGPA in the US who continue to suffer from debilitating symptoms.
FDA OKs New Option for Rare Immune-Mediated Vasculitis
WEB2 days ago · by Ian Ingram, Managing Editor, MedPage Today September 18, 2024. The FDA approved the asthma drug benralizumab (Fasenra) as a new therapy for adults with eosinophilic granulomatosis with ...
Benralizumab versus Mepolizumab for Eosinophilic …
WEBFeb 23, 2024 · This report describes the results of a phase 3 trial that evaluated the efficacy and safety of benralizumab (every 4 weeks) as compared with mepolizumab over 52 weeks in patients with relapsing...
Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis
WEBJun 26, 2024 · Benralizumab is an eosinophil-depleting anti–interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear.
Benralizumab for the Prevention of COPD Exacerbations
WEBMay 20, 2019 · Benralizumab is an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody that induces direct, rapid, and substantial eosinophil depletion by means of antibody-dependent cellular...
Update on the MESSINA Phase III trial for Fasenra in eosinophilic ...
WEBOct 25, 2022 · FitzGerald JM, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 …
Benralizumab approved for treatment of eosinophilic ... - Healio
WEB18 hours ago · The FDA approved AstraZeneca’s Fasenra for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis, or EGPA, according to a company press release.The approval comes ...